NCT05201066 2026-01-07Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.NovartisPhase 2 Active not recruiting33 enrolled